Alkermes PLC Form 4 insider transactions

David Joseph Gaffin, EVP, CLO of Alkermes, reports acquisition and disposal of ordinary shares and derivative securities.

Iain Michael Brown, CFO of Alkermes plc, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Blair C. Jackson, EVP and Chief Operating Officer of Alkermes plc, reports the acquisition and disposal of ordinary shares and derivative securities.

Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reports transactions involving ordinary shares and derivative securities, including the exercise of restricted stock units and the grant of new stock options and restricted stock units.

Alkermes CEO Richard F. Pops was granted stock options to purchase 293,921 ordinary shares on February 19, 2025.

Craig Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, exercised stock options and sold shares of ordinary stock under a pre-arranged 10b5-1 trading plan.

Richard F. Pops, CEO of Alkermes plc, reports acquisition of shares through vesting of restricted stock units and disposal of shares to cover tax obligations.

Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes plc, reports acquiring shares through vesting of restricted stock units and disposing of shares to cover tax obligations.

EVP and Chief Operating Officer of Alkermes, Blair Curtis Jackson, reports acquisition and disposal of ordinary shares following vesting of performance-based restricted stock units.

EVP and Chief Medical Officer of Alkermes, Craig C. Hopkinson, reports acquisition of shares through vesting of restricted stock units and subsequent disposal to cover tax obligations.

Alkermes' EVP, CLO, David Joseph Gaffin, reports acquisition and disposal of ordinary shares following the vesting of performance-based restricted stock units.

Iain Michael Brown, CFO of Alkermes plc, reports the acquisition of 24,565 ordinary shares through vesting of performance-based restricted stock units and the disposal of 7,514 shares to cover tax obligations.

Alkermes EVP Craig C. Hopkinson exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Craig C. Hopkinson, EVP R&D and Chief Medical Officer at Alkermes plc, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Cato T. Laurencin of Alkermes plc. engaged in multiple stock transactions, including acquisitions and disposals of ordinary shares and derivative securities, under a pre-arranged 10b5-1 trading plan.

Craig C. Hopkinson, EVP R&D and Chief Medical Officer at Alkermes plc, sold 9,221 ordinary shares at $31.50 per share under a pre-arranged 10b5-1 trading plan.

Craig C. Hopkinson, EVP R&D and Chief Medical Officer at Alkermes plc, sold 14,349 ordinary shares at a weighted average price of $30.7722, as part of a pre-arranged 10b5-1 trading plan.

Christian Todd Nichols, SVP and Chief Commercial Officer at Alkermes plc, sold 5,208 ordinary shares at $29.15 per share on November 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Alkermes EVP Craig C. Hopkinson exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reported the sale of 10,471 ordinary shares on November 6, 2024, at a weighted average price of $29.5262.

David Joseph Gaffin, EVP, CLO of Alkermes, Inc., reports the vesting and subsequent disposal of ordinary shares related to restricted stock units.

Director Christopher I. Wright reported the disposal of Alkermes plc shares following the vesting of restricted stock units on June 29, 2024.

Director Frank Anders Wilson reports the disposition of Alkermes plc ordinary shares following the vesting of restricted stock units.

Director Nancy Snyderman reports the vesting and disposal of restricted stock units and a transaction related to tax obligations.

Director Brian P. McKeon reports acquisition and disposal of Alkermes plc ordinary shares, including transactions related to restricted stock units.

Director Cato T. Laurencin reports transactions involving Alkermes plc ordinary shares, including the vesting of restricted stock units and subsequent disposal of shares to cover tax obligations.

Director Richard Gaynor reports the disposition of Alkermes plc ordinary shares following the vesting of restricted stock units.

Director David Angelo Daglio Jr. reports acquisition and disposal of Alkermes plc ordinary shares and restricted stock units.

Director Shane Cooke reports acquisition and disposal of Alkermes plc ordinary shares and restricted stock units on June 29, 2024.

Director Emily Peterson Alva reports exercising stock options and disposing of shares of Alkermes plc on June 29, 2024.